Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sublingually administered asenapine was approved in March 2015 by the United States Food and Drug Administration for patients aged 10-17 years with an acute manic or mixed episode associated with bipolar I disorder (BP-1). This is the first long-term safety and tolerability study of asenapine in this population. METHODS: Following the 3-week randomized, double-blind, placebo-controlled trial of patients aged 10-17 years with an acute manic or mixed episode associated with BP-1, patients could enroll in this flexible-dose (2.5-10 mg twice daily) open-label extension (OLE) study for an additional 50 weeks, conducted from August 2011 to September 2014 in the United States and Russia. Treatment-emergent adverse events (TEAEs) were assessed and predefined TEAEs of interest reported in addition to metabolic and anthropometric parameters. The Young Mania Rating Scale (YMRS) and Clinical Global Impressions scale in bipolar illness (CGI-BP) were used to assess effectiveness. RESULTS: A total of 321 patients (lead-in study treatment: placebo, n = 80; asenapine, n = 241) were included; 267 (83.2 %) reported one or more TEAE and 181 (56.4 %) discontinued early, 48 (15.0 %) due to TEAEs. Of the predefined TEAEs of interest, combined somnolence/sedation/hypersomnia occurred most frequently (42.4 %) followed by oral hypoesthesia/dysgeusia (7.5 %). In total, 109 (34.8 %) patients experienced clinically significant weight gain (≥7 % increase). No clinically meaningful changes were noted for laboratory parameters measured. Eighteen patients met the criteria for new-onset metabolic syndrome (MBS) post-baseline during the extension study, whereas 10 patients who met MBS criteria at baseline did not meet MBS criteria at endpoint. A total of 12 patients met MBS at baseline and endpoint. Mean change in YMRS total score from OLE baseline was -9.2 points at week 50, and change in CGI-BP severity overall score was similar among all treatment groups (those who initially received asenapine and those who initially received placebo). After 26 weeks of treatment in the OLE, 79.2 % of patients were classified as YMRS 50 % responders relative to acute trial baseline. CONCLUSIONS: Asenapine was generally well tolerated in pediatric patients with BP-1 during ≤50 weeks of open-label treatment; among predefined TEAEs of interest, the combination of somnolence/sedation/hypersomnia was the most common. Trial registration ClinicalTrials.gov: NCT01349907.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although there has been far less experience with asenapine than with other medications discussed in this section, a recent open‐label extension study suggests continual reduction in manic symptoms over 50 weeks (level 4).608”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 1×
“, suicidal ideation, suicidal behavior, and/or non-suicidal self-injurious behavior) were summarized based on responses to the C-SSRS at each visit [13].”
MethodTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003
Spearing, M. K., Post, R. M., Leverich, G. S., Brandt, D., & Nolen, W. (1997) · Psychiatry Research · doi:10.1016/s0165-1781(97)00123-6 · Cited by 978
The metabolic syndrome in children and adolescents
Zimmet, P., Alberti, G., Kaufman, F., Tajima, N., Silink, M., Arslanian, S., Wong, G., Bennett, P., Shaw, J., & Caprio, S. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60958-1 · Cited by 937
Perlis, R. H., Miyahara, S., Marangell, L. B., Wisniewski, S. R., Ostacher, M., DelBello, M. P., Bowden, C. L., Sachs, G. S., & Nierenberg, A. A. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.022 · Cited by 852
Clinical Course of Children and Adolescents With Bipolar Spectrum Disorders
Birmaher, B., Axelson, D., Strober, M., Gill, M. K., Valeri, S., Chiappetta, L., Ryan, N., Leonard, H., Hunt, J., Iyengar, S., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.175 · Cited by 655
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Goldstein, B. I., Birmaher, B., Carlson, G. A., DelBello, M. P., Findling, R. L., Fristad, M., Kowatch, R. A., Miklowitz, D. J., Nery, F. G., Perez‐Algorta, G., et al. (2017) · Bipolar Disorders · doi:10.1111/bdi.12556 · Cited by 234
Self-citationYatham, L. N., Chakrabarty, T., Bond, D. J., Schaffer, A., Beaulieu, S., Parikh, S. V., McIntyre, R. S., Milev, R. V., Alda, M., Vázquez, G. H., et al. (2021) · Bipolar Disorders · doi:10.1111/bdi.13135 · Cited by 136
A Focused Review on the Treatment of Pediatric Patients with Atypical Antipsychotics
Lee, E. S., Vidal, C., & Findling, R. L. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2018.0037 · Cited by 85
Self-citationA Meta-Analysis of Antipsychotic-Induced Hypo- and Hyperprolactinemia in Children and Adolescents
Krøigaard, S. M., Clemmensen, L., Tarp, S., & Pagsberg, A. K. (2022) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2021.0140 · Cited by 53
Maintenance Pharmacological Treatment of Juvenile Bipolar Disorder: Review and Meta-Analyses
Yee, C. S., Hawken, E. R., Baldessarini, R. J., & Vázquez, G. H. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz034 · Cited by 48
A Review of Asenapine in the Treatment of Bipolar Disorder
Vieta, E., & Montes, J. M. G. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0592-2 · Cited by 45
Asenapine: an atypical antipsychotic with atypical formulations
Musselman, M. A., Faden, J., & Citrome, L. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211035269 · Cited by 41
Prescriber's Guide – Children and Adolescents: Stahl's Essential Psychopharmacology
Stahl, S. M. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108561402 · Cited by 35
Pediatric Bipolar Disorder: Challenges in Diagnosis and Treatment
Wozniak, J. R., O’Connor, H., Iorini, M., & Ambrose, A. J. H. (2024) · Pediatric Drugs · doi:10.1007/s40272-024-00669-z · Cited by 24
Safety considerations in the psychopharmacology of pediatric bipolar disorder
Sun, A. Y., Woods, S., Findling, R. L., & Stepanova, E. A. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1637416 · Cited by 21
Self-citationAdvances in the psychopharmacotherapy of bipolar disorder type I
Sleem, A., & El‐Mallakh, R. S. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1893306 · Cited by 16
Clinical Handbook for the Diagnosis and Treatment of Pediatric Mood Disorders
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200 · Cited by 14
Second-Generation Antipsychotic Drugs for Children and Adolescents
Onishi, Y., Mikami, K., Kimoto, K., Watanabe, N., Takahashi, Y., Akama, F., Yamamoto, K., & Matsumoto, H. (2020) · Journal of Nippon Medical School · doi:10.1272/jnms.jnms.2021_88-108 · Cited by 13
Asenapine pharmacokinetics and tolerability in a pediatric population
Dogterom, P., Riesenberg, R. A., de Greef, R., Dennie, J. G., Johnson, M. G., Reddy, V., Miltenburg, A. M. M., Findling, R. L., Jakate, A. S., Carrothers, T. J., et al. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s171475 · Cited by 13
Self-citationAsenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review
Stepanova, E. A., Grant, B., & Findling, R. L. (2017) · Pediatric Drugs · doi:10.1007/s40272-017-0274-9 · Cited by 11
Self-citationSharma, D., Higgins, O., Sawicki, A., Ramamurthy, P., Field, B., Hussein, P., Singh, K. A., & Ranjitkar, S. (2025) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.13639 · Cited by 8
Neurological Adverse Effects of Antipsychotic Medication in Children and Young People
Besag, F., Vasey, M. J., Hollis, C. P., & Taylor, D. M. (2026) · Pediatric Drugs · doi:10.1007/s40272-025-00730-5 · Cited by 8
Asenapine for the treatment of bipolar disorder
Marazziti, D., Mucci, F., Falaschi, V., & Dell’Osso, L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1617849 · Cited by 8
Asenapine, iloperidone and lurasidone exposures in young children reported to U.S. poison centers
Stassinos, G. L., & Klein‐Schwartz, W. (2017) · Clinical Toxicology · doi:10.1080/15563650.2017.1388385 · Cited by 7
Amerio, A., Arduino, G., Fesce, F., Costanza, A., Aguglia, A., Amore, M., & Serafini, G. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2386429 · Cited by 7
Research Status in Clinical Practice Regarding Pediatric and Adolescent Bipolar Disorders
Liu, L., Meng, M., Zhu, X., & Zhu, G. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.882616 · Cited by 4
Cariprazine in Autism Spectrum Disorder and Intellectual Disability Disorder
Cohen, L. S. (2019) · Global Journal of Intellectual & Developmental Disabilities · doi:10.19080/gjidd.2019.06.555694 · Cited by 4
Chapter 13. Management of Suicidal Youth
Clarke, S. B., Ragan, E., & Berk, M. S. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.lg13 · Cited by 3
Chapter 15. School-Based Interventions for Pediatric-Onset Mood Disorders
Joshi, S. V., & Jassim, N. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.lg15 · Cited by 2
Chapter 31. Ziprasidone and Asenapine
Newcomer, J. W., Lipsey, J., Strassnig, M., & Citrome, L. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as31 · Cited by 1
Chapter 8. Evidence-Based Psychotherapies for Pediatric Bipolar Disorders
Miklowitz, D. J. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.lg08 · Cited by 1
Chue, P. S., & Siraki, A. G. (2017) · Side effects of drugs annual · doi:10.1016/bs.seda.2017.06.029 · Cited by 1
Atkinson, S. D., Bachinsky, M., Raiter, Y., Abreu, P. C., Ianos, C. A., Chappell, P. B., & Findling, R. L. (2022) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2022.0030 · Cited by 1
Self-citationPsychopharmacology for Pediatric Bipolar Disorder
Hobbs, E., Reed, R., Dorfman, J., & Robb, A. S. (2024) · Springer eBooks · doi:10.1007/978-3-031-57472-6_17
Carlson, G. A. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.lg03
Chapter 12. Assessment, Prognosis, and Treatment of Subthreshold Mood Symptoms
Hafeman, D., & Spada, M. L. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.lg12
Chapter 7. Evidence-Based Psychotherapies for Pediatric Depressive Disorders
Santamarina, P., & West, M. P. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.lg07
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.bm03
Chapter 10. Pharmacotherapy for Pediatric Bipolar Disorders
Patino, L. R., & DelBello, M. P. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.lg10
Chapter 6. Neuroscience of Childhood-Onset Bipolar Disorder: Translation of Science to Service
May, A., Weinstein, S. M., Carbray, J. A., & Pavuluri, M. N. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.lg06
Chapter 1. Principles of Assessment of Mood Disorders in Childhood
Singh, M. K. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.lg01
Chapter 2. DSM-5 Diagnosis of Mood Disorders in Children and Adolescents
Meter, A. V. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.lg02
Appendix A. Resources and Readings
Singh, M. K. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.bm01
Chapter 16. Preventative and Emerging Pharmacological and Nonpharmacological Treatments
Dickstein, D. P., & Croarkin, P. E. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.lg16
Appendix B. Quick Reference Facts for the Treatment of Pediatric Mood Disorders
Singh, M. K. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.bm02
Chapter 9. Pharmacotherapy for Pediatric Depression
Kim, G.-M., Gandhi, R., & Cullen, K. R. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.lg09
Chapter 14. Management of Common Co-occurring Conditions in Pediatric Mood Disorders
Larios, D. A., & Galanter, C. A. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.lg14
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.index
Chapter 4. Principles of Treatment of Mood Disorders Across Development
Zalpuri, I., & Singh, M. K. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.lg04
Chapter 5. Neuroscience of Early-Onset Depression
Rao, U., & Lei, T. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.lg05
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.fm01
Chapter 11. Longer-Term Management of Mood Disorders in Youth
Diler, R. S., & Birmaher, B. B. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.lg11
Mixed Features and Rapid Cycling
Gnielka, V., Magalhães, L. S., Anzolin, A. P., Machado, B. V. D., da Silva, V. M. M., & Kauer‐Sant’Anna, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-85519-1_21
Staging, Functioning, and Cognition
Kupka, R., Scott, J. L., & Hillegers, M. H. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-85519-1_10
Robb, A. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-51147-6.00016-8
Pharmacologic Treatment Options for Bipolar Disorder in Children and Adolescents
Stepanova, E. A., & Findling, R. L. (2017) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-017-0125-x
Self-citationEarly pharmacological interventions in youth
Kaplin, D. B., Stepanova, E. A., Grant, B., Budimirovic, D. B., & Findling, R. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812347-8.00011-7
Self-citationStahl, S. M., & Strawn, J. R. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009267526.006
Salman Velasco, M. A. (2018) · Institutional Repository of the University of El Salvador (University of El Salvador)
da Silva, N. R. W. (2018) · Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)
Metadata
- Authors
- Findling, R. L., Landbloom, R. L., Mackle, M., Wu, X., Snow-Adami, L., Chang, K., & Durgam, S.
- Affiliations
- Kennedy Krieger Institute (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Allergan (United States) (US)
- Lucile Packard Children's Hospital (US)
- Corresponding author
- Findling, Robert L.
- Venue
- Pediatric Drugs
- Published
- 2016-07-26
- Volume
- 18
- Issue
- 5
- Pages
- 367-378
- ISSN
- 1174-5878 (ISSN-L)
- 1179-2019
- PMC
- PMC5018262
- OpenAlex
- W2479858292
- Cited by
- 53
- References
- 26
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2022: 3 · 2021: 3 · 2020: 1 · 2019: 26 · 2018: 6 · 2017: 6
- FWCI
- 11.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Pediatric Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Merck
- Forest Laboratories
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- asenapine, bipolar I disorder, pediatric bipolar disorder, manic episodes, long-term safety, tolerability, treatment-emergent adverse events, sleepiness, weight gain, metabolic syndrome, open-label extension, Young Mania Rating Scale, antipsychotic efficacy
- MeSH terms
- Adolescent, Bipolar Disorder, Child, Dibenzocycloheptenes, Double-Blind Method, Female, Heterocyclic Compounds, 4 or More Rings, Humans, Male, Psychiatric Status Rating Scales, Russia, Antipsychotic Agents, United States, United States Food and Drug Administration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.